|PRODUCT NAME||CATALOG #||UNIT||PRICE||QTY||FAVORITES|
|EX 527||sc-203044||5 mg||$80.00||
EX 527 is a potent and selective inhibitor of the SIRT1 class III histone deacetylase enzyme, thought to block the release of deacetylated peptide and O-acetyl-ADP-ribose from the enzyme following the deacetylation process. EX 527 has been used a powerful tool for studying the relationship between SIRT1 and cell regulation. The deacetylation of cortactin, a protein responsible for rearrangements of the actin cytoskeleton, is associated with cell motility and possibly tumorigenesis, and blocking of this deacetylation by EX 527 correlated to a decrease in cell motility. Blocking of SIRT1 by EX 527 also demonstrated that deacetylation of the important tumor suppressor protein p53 is mediated by SIRT1 as well. EX 527 inhibits other sirtuin family deacetylases only at much higher concentrations (IC50 = 19.6 and 48.7 μM for SIRT2 and SIRT3, respectively).
1. Napper, Andrew D., et al., 2005. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. Journal of medicinal chemistry. 48(25): 8045-54. PMID: 16335928
2. Solomon, Jonathan M., et al., 2006. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Molecular and cellular biology. 26(1): 28-38. PMID: 16354677
3. Milne, Jill C., et al., 2007. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 450(7170): 712-6. PMID: 18046409
4. Zhang, Y., et al., 2009. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene. 28(3): 445-60. PMID: 18850005
See how others have used EX 527. Click on the entry to view the PubMed entry .
PMID: # 26891914
Graham, RM. et al. 2016. Resveratrol augments ER stress and the cytotoxic effects of glycolytic inhibition in neuroblastoma by downregulating Akt in a mechanism independent of SIRT1. Experimental & molecular medicine. 48: e210.
PMID: # 26307266
Guida, N. et al. 2015. Resveratrol via sirtuin-1 downregulates RE1-silencing transcription factor (REST) expression preventing PCB-95-induced neuronal cell death. Toxicology and applied pharmacology. 288: 387-98.
PMID: # 26052531
Wielgosz, MM. et al. 2015. Generation of a lentiviral vector producer cell clone for human Wiskott-Aldrich syndrome gene therapy. Molecular therapy. Methods & clinical development. 2: 14063.
PMID: # 25401748
Yang, Y. et al. 2015. Melatonin prevents cell death and mitochondrial dysfunction via a SIRT1-dependent mechanism during ischemic-stroke in mice. Journal of pineal research. 58: 61-70.
PMID: # 25710021
He, W. et al. 2015. Advanced glycation end products induce endothelial-to-mesenchymal transition via downregulating Sirt 1 and upregulating TGF-β in human endothelial cells. BioMed research international. 2015: 684242.
PMID: # 24990896
Quadri, S. et al. 2014. Regulation of (pro)renin receptor expression in mIMCD via the GSK-3β-NFAT5-SIRT-1 signaling pathway. American journal of physiology. Renal physiology. 307: F593-600.
PMID: # 24982422
Rodríguez, M. et al. 2014. The Unfolded Protein Response and the Phosphorylations of Activating Transcription Factor 2 in the trans-Activation of il23a Promoter Produced by β-Glucans J Biol Chem.. 289: 22942-22957.
PMID: # 22893703
Alvarez, Y. et al. 2012. Sirtuin 1 is a key regulator of the interleukin-12 p70/interleukin-23 balance in human dendritic cells. The Journal of biological chemistry. 287: 35689-701.
PMID: # 21320266
Kim, D. et al. 2011. Therapeutic potential of panduratin A, LKB1-dependent AMP-activated protein kinase stimulator, with activation of PPARα/δ for the treatment of obesity. Diabetes Obes Metab. 13: 584-593.
PMID: # 21320266
Kim, D. et al. 2011. Therapeutic potential of panduratin A, LKB1-dependent AMP-activated protein kinase stimulator, with activation of PPARα/δ for the treatment of obesity. Diabetes, obesity & metabolism. 13: 584-93.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2017 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.